Compare Ishares Msci Brazil ETF (EWZ) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs IDEXX Laboratories, Inc. — how do they compare? Ishares Msci Brazil ETF trades at $43.54 (market cap $11.30B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.6× Ishares Msci Brazil ETF's market cap, and Ishares Msci Brazil ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| EWZ | IDXX | |
|---|---|---|
Market Cap | $11.30B | $40.43B |
Volume | 44,036,597 | 692,164 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.00 | $766.68 |
52-Week Low | $28.79 | $504.70 |
Typical Hold Time | 50 Days | 46 Days |
Enterprise Value | — | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, is trading at $43.54, up 2.76% today, with strong bullish momentum from moving averages but overbought RSI signals. The ETF is positioned as a diversification play against U.S. tech concentration, benefiting from Brazil's commodity exposure and election-driven optimism. Recent unusual options activity and institutional buying reflect heightened investor interest ahead of October's presidential election.
The outlook hinges on Brazil's election outcome and commodity trends, offering asymmetric upside via call spreads. Risks include political volatility, U.S. tariff impacts, and competition from lower-fee Brazil ETFs like FLBR. Wall Street sentiment is cautiously optimistic, with the trade acting as a hedge against AI-driven U.S. market risks.
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
